晚期心力衰竭中的巴罗反射激活疗法:长期随访
Dong Wang1, Johanna Mueller-Leisse1, Henrike A K Hillmann1
1Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
ESC heart failure
|October 8, 2024
概括
巴罗受体激活疗法 (BAT) 对心力衰竭与减少射出分数 (HFrEF) 提供长期益处. 在长时间的随访期间,这种疗法显著改善了HFrEF患者的症状和左心室喷射率 (LVEF).
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭管理的管理
背景情况:
- 巴罗受体激活疗法 (BAT) 是一种新兴的心力衰竭治疗方法,减少排气分数 (HFrEF).
- 现有的关于BAT在HFrEF患者的长期疗效的数据有限.
- 本研究调查了HFrEF患者队列中BAT的长期结果.
研究的目的:
- 评估巴罗受体激活疗法 (BAT) 对心力衰竭患者的长期影响.
- 为了评估症状负担的变化,左心室喷射率 (LVEF) 和心脏生物标志物在延长后续期间.
主要方法:
- 对23名在2014年至2023年期间接受了BAT的HFrEF患者进行了回顾性单心研究.
- 在随访前和随访期间评估症状负担 (NYHA分类),心声回声 (LVEF) 和NT-proBNP水平.
- 平均随访时间为3±2年,最长为7.5年.
主要成果:
- 最佳技术证明了显著的长期改善:52%的患者在1年后显示NYHA分类降低,有些人持续受益.
- 左心室喷射分数 (LVEF) 在1年后显著改善了9% (P < 0.001) 和2年后显著改善了11% (P = 0.005).
- 在2年后,N-终端B型亲尿素 (NT-proBNP) 水平显著下降 (P = 0.039). 在植入过程中发生了一种并发症 (4%).
结论:
- 对HFrEF患者来说,巴罗受体激活疗法 (BAT) 在NYHA分类中提供了实质性和持久的减少,并改善了LVEF.
- 该研究强调了BAT的长期有效性和潜在益处,作为治疗心力衰竭的治疗选择,减少了喷射分数.
- 在临时长期跟踪期间,NT-proBNP水平下降,进一步支持了BAT的积极影响.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:22Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:28Mitral Regurgitation IV: Nursing Management
3
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
3
01:22Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320